{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:58:12Z","timestamp":1793141892986,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["14-21053S"],"award-info":[{"award-number":["14-21053S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1332\/10"],"award-info":[{"award-number":["1332\/10"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","award":["IGAPrF 2015 025"],"award-info":[{"award-number":["IGAPrF 2015 025"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LD14019"],"award-info":[{"award-number":["LD14019"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.bcp.2015.04.003","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T02:02:08Z","timestamp":1429236128000},"page":"133-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells"],"prefix":"10.1016","volume":"95","author":[{"given":"Vojtech","family":"Novohradsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Zerzankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Stepankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oldrich","family":"Vrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raji","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kasparkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Brabec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.04.003_bib0255","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.bcp.2015.04.003_bib0260","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/0929867033368484","article-title":"Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways","volume":"10","author":"Fuertes","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0265","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.20045","article-title":"Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid","volume":"92","author":"Marchion","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0270","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2015.04.003_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.09.018","article-title":"Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer","volume":"329","author":"Diyabalanage","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2015.04.003_bib0280","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1021\/ic00109a004","article-title":"Carboxylation of kinetically inert platinum(IV) hydroxy complexes - an entree into orally-active platinum(IV) antitumor agents","volume":"34","author":"Giandomenico","year":"1995","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0285","doi-asserted-by":"crossref","first-page":"17356","DOI":"10.1073\/pnas.0809154105","article-title":"Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles","volume":"105","author":"Dhar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2015.04.003_bib0290","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1021\/ja803036e","article-title":"Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device","volume":"130","author":"Dhar","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2015.04.003_bib0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/bc070031k","article-title":"Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature","volume":"19","author":"Mukhopadhyay","year":"2008","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0300","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp200597r","article-title":"Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy","volume":"9","author":"Yang","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2015.04.003_bib0305","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jinorgbio.2013.09.003","article-title":"Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells","volume":"129","author":"Alessio","year":"2013","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0310","first-page":"2791","article-title":"Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells","volume":"32","author":"Jasek","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2015.04.003_bib0315","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cellimm.2013.04.011","article-title":"Lipopolysaccharide prevents valproic acid-induced apoptosis via activation of nuclear factor-kappa B and inhibition of p53 activation","volume":"282","author":"Tsolmongyn","year":"2013","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bcp.2015.04.003_bib0320","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2015.04.003_bib0325","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00894-011-1240-z","article-title":"Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations","volume":"18","author":"Bermudez-Lugo","year":"2012","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.bcp.2015.04.003_bib0330","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.toxlet.2013.10.035","article-title":"Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells","volume":"224","author":"Kwiecinska","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2015.04.003_bib0335","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.02.042","article-title":"Enhancing the apoptotic and therapeutic effects of HDAC inhibitors","volume":"280","author":"Frew","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2015.04.003_bib0340","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bcp.2015.04.003_bib0345","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/chem.201203159","article-title":"Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design","volume":"19","author":"Zhang","year":"2013","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.bcp.2015.04.003_bib0350","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1535-7163.MCT-07-0410","article-title":"Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo","volume":"6","author":"Moser","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2015.04.003_bib0355","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ica.2012.06.005","article-title":"Metallo-drugs in the treatment of malignant pleural mesothelioma","volume":"393","author":"Zanellato","year":"2012","journal-title":"Inorg. Chim. Acta"},{"key":"10.1016\/j.bcp.2015.04.003_bib0360","first-page":"5618","article-title":"A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity","volume":"54","author":"Kelland","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2015.04.003_bib0365","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0162-0134(99)00141-5","article-title":"Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance","volume":"77","author":"Kelland","year":"1999","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0370","first-page":"1649","article-title":"Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline","volume":"55","author":"Fan","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2015.04.003_bib0375","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1039\/c3cc48740g","article-title":"Conjugation of vitamin E analog \u03b1-TOS to Pt(IV) complexes for dual-targeting anticancer therapy","volume":"50","author":"Suntharalingam","year":"2014","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bcp.2015.04.003_bib0380","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kramer","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2015.04.003_bib0385","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1210\/en.2003-0940","article-title":"Valproate potentiates androgen biosynthesis in human ovarian theca cells","volume":"145","author":"Nelson-DeGrave","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2015.04.003_bib0390","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2015.04.003_bib0395","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.toxlet.2009.08.018","article-title":"5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats","volume":"191","author":"Tikoo","year":"2009","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2015.04.003_bib0400","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2199-11-49","article-title":"Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest","volume":"11","author":"Koprinarova","year":"2010","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.bcp.2015.04.003_bib0405","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1021\/mp300038f","article-title":"Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)]","volume":"9","author":"Brabec","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2015.04.003_bib0410","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1242\/jcs.104.2.317","article-title":"Condensation of the chromatin at the membrane of an apoptotic nucleus is not associated with activation of an endonuclease","volume":"104","author":"Oberhammer","year":"1993","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.bcp.2015.04.003_bib0415","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.taap.2011.03.004","article-title":"Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: Role of biotransformation and temporal relationship with onset of toxicity","volume":"252","author":"Kiang","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2015.04.003_bib0420","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00001.2006","article-title":"Mechanisms of liver injury. III. Role of glutathione redox status in liver injury","volume":"291","author":"Han","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcp.2015.04.003_bib0425","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/187152007779314062","article-title":"The role of sulfur in platinum anticancer chemotherapy","volume":"7","author":"Wang","year":"2007","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0430","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of cisplatin-DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2015.04.003_bib0435","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1021\/cr020010d","article-title":"Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance","volume":"103","author":"Fuertes","year":"2003","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2015.04.003_bib0440","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2015.04.003_bib0445","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/bjc.1992.419","article-title":"Reduced drug accumulation as a major mechanism of acquired-resistance to cisplatin in a human ovarian-carcinoma cell-line. Circumvention studies using novel platinum (II) and (IV) ammine amine complexes","volume":"66","author":"Loh","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2015.04.003_bib0450","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1021\/jm0708275","article-title":"Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake","volume":"50","author":"Oldfield","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0455","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1021\/om800207t","article-title":"Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds","volume":"27","author":"Mendoza-Ferri","year":"2008","journal-title":"Organometallics"},{"key":"10.1016\/j.bcp.2015.04.003_bib0460","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00775-010-0676-4","article-title":"Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling","volume":"15","author":"Gramatica","year":"2010","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0465","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1021\/ic200607j","article-title":"Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes","volume":"50","author":"Liu","year":"2011","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bcp.2015.04.003_bib0470","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1242\/jcs.084285","article-title":"Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium","volume":"124","author":"Terbach","year":"2011","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2015.04.003_bib0475","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml1001954","article-title":"Short-chain HDAC inhibitors differentially affect vertebrate development and neuronal chromatin","volume":"2","author":"Fass","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2015.04.003_bib0480","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1039\/c2mb25136a","article-title":"A combined approach for the study of histone deacetylase inhibitors","volume":"8","author":"Cincarova","year":"2012","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.bcp.2015.04.003_bib0485","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2015.04.003_bib0490","first-page":"2013","article-title":"HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells","author":"Ward","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.04.003_bib0495","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11306-009-0192-0","article-title":"Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation","volume":"6","author":"Alcarraz-Vizan","year":"2010","journal-title":"Metabolomics"},{"key":"10.1016\/j.bcp.2015.04.003_bib0500","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1039\/c4dt00911h","article-title":"Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one","volume":"43","author":"Gabano","year":"2014","journal-title":"Dalton Trans."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215001963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215001963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:59:45Z","timestamp":1757768385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0006295215001963"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.04.003","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}